Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Overview

OUR STUDY

THE PROMISE study is the first study to test healthy people who may be at risk for early warning signs of a blood cancer called multiple myeloma.

We will further study people who test positive for these early warning signs of multiple myeloma so that we can learn how to prevent them from developing into cancer.

OUR GOALS

This study aims to make multiple myeloma a cancer that is preventable.

Who can join and get screened at no cost?

2 groups of U.S. adults, age 45-75, qualify for a free screening:

  1. African Americans AND / OR
  2. People of Any Race Who Have a parent, sibling, or child with multiple myeloma or one these related conditions:
    • ​Monoclonal Gammopathy of Undetermined Significance (MGUS)
    • Smoldering Multiple Myeloma
    • Waldenström Macroglobulinemia
SparkCures ID 979
Trial Phase Observational Trial
Enrollment 50000 Patients
Tags
Trial Sponsors
  • Dana-Farber Cancer Institute
Trial Collaborators
  • Stand Up To Cancer
NCT Identifier

NCT03689595

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Age ≥ 45 and ≤75
  • AA race (self-identified) and/or first-degree relative of a patient with plasma cell dyscrasia such as MGUS, SMM, multiple myeloma, and Waldenström Macroglobulinemia

Exclusion Criteria:

  • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Massachusetts

Resources

There are no resources, links or videos to display for this clinical trial.